ArticleGastro hep advances2026
Pulsed Low-Dose-Rate Chemoradiation Induces Stromal Reprogramming in Pancreatic CAF-Generated ECM: Quantification by the HOST-Factor.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04452357 (RT-155), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
RT-155: Utilizing Pulsed Low-dose-rate (PLDR) Radiation to Prevent de Novo Stromal Activation; a Neoadjuvant Pancreatic Adenocarcinoma Phase I Trial
Who cites it
2 citing papers in PubMed.
- Challenges and opportunities in combining radiotherapy and immunotherapy for localized pancreatic cancer.Nature reviews. Gastroenterology & hepatology · 2026Review
- Radiation-Induced Alterations in Cancer-Associated Fibroblasts: Drivers of Tumor Radioresistance and Therapeutic Targets.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Background and Aims: Pancreatic cancer remains highly lethal, with limited treatment options, in part due to its extensive and complex desmoplastic tumor microenvironment (TME). We investigated the in vitro use of pulsed low-dose-rate radiation (PLDR) as an alternative to conventional radiotherapy, aiming to counteract a key pro-tumoral effect of standard chemoradiation on the TME. Additionally, we introduced a novel approach for quantifying pro- vs anti-tumoral stromal function in vitro. Methods: We utilized an established 3-dimensional, in vivo-mimetic cancer-associated fibroblast (CAF) functional unit culture system to model and alter TME behavior. To comprehensively assess the impact of PLDR, we developed the Harmonic Output of Stromal Traits Factor (HOST-Factor), a composite score integrating multiple function-informing stromal biomarkers. Results: We found that PLDR combined with chemotherapy induced a functional shift in the extracellular matrix (ECM) produced by chemoradiotherapy-treated CAFs. These functional units of CAFs and their self-generated ECMs (CAF Conclusion: Our findings suggest that PLDR may restrict desmoplastic expansion and improve the therapeutic efficacy of chemoradiotherapy. The HOST-Factor provides a novel, quantitative tool for assessing stromal function and may inform future treatment strategies. These results support the ongoing NCT04452357 clinical trial, which is evaluating the safety and impact of escalated PLDR-based chemoradiation in the neoadjuvant treatment of pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.